PayPal, the Bay Area tech giant, has unveiled plans for a significant workforce reduction, marking a 9% cut almost exactly a year after a similar layoff round. CEO Alex Chriss conveyed the decision to employees in a Tuesday email, emphasizing the necessity of the move. The reduction will encompass both layoffs and the elimination of open positions, occurring gradually over the course of the year. According to a company spokesperson, 311 employees based in San Jose are affected by the layoffs. Chriss, who assumed the role of CEO in September, justified the decision as crucial for optimizing business operations and facilitating agile responses to customer needs. Despite reporting a $1 billion profit from July to September, the company aims to right-size its operations for sustained growth. PayPal, which includes subsidiaries like Venmo and Xoom, had 29,900 employees at the end of 2022. The announced 9% cut suggests approximately 2,500 jobs will be affected. Affected employees will be notified by the end of the week, with many expressing their situations on platforms like LinkedIn. This announcement follows a trend of layoffs in the Bay Area’s tech industry, with companies like Google, Discord, eBay, Unity Software, and Twitch also implementing workforce reductions in January, signaling a challenging start for the sector in 2024.
Bay Area Tech Leader PayPal Reveals Significant Workforce Reduction, One Year After Previous Layoffs
Leaked Sony Xperia 10 VII Renders Reveal Major Design Overhaul
Tesla Quietly Pulls Plug on Model S and Model X Sales in Germany and Beyond
Temu Targets Germany’s Grocery Market: A New Competitor for Aldi, Lidl, and More
NFC Gets a Major Upgrade: New Standard Expands Range Fourfold
American Coastal Insurance Corp.: Focused on Residential and Commercial Insurance Solutions
HUAWEI FIT 4 Pro: A Smartwatch That Delivers Without Breaking the Bank
Direxion Daily S&P Biotech Bull 3X: A High-Octane Bet on the Biotech Sector
Nvidia’s Warp Python Framework for CUDA Now Open Source
Biomea Fusion Advances Targeted Therapies for Cancer and Diabetes